SUBCUTANEOUS ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A REAL-LIFE EXPERIENCE

Título traducido de la contribución: Abatecept Subcutáneo en pacientes con artritis reumatoide: una experiencia en la vida real 2019

Juan C. Sarmiento-Monroy, C. Villota-Eraso, M. J. Mantilla-Ribero, N. Molano-Gonzalez, M. Rodriguez-Jimenez, Adriana Rojas-Villarraga, Rubeacuten D. Mantilla

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

61 Citas (Scopus)

Resumen

A total of 159 patients were included. Baseline characteristics of patients were as follows: female gender 84%, median age of 54 years (IQR 16), median disease duration 10 years (11), RF positive 96%, anti-CCP positive 89%, erosive disease 55%, median DAS28-CRP 5.0 (2), and median RAPID3 17 (10). Concomitant use of methotrexate and SC ABA monotherapy were reported at 52% and 30% respectively. Demographics and disease characteristics were similar for all groups, except for baseline DAS28-CRP, and RAPID3 in the group that switched route of administration. The interaction between time and group was significant (p = 0.0073) for RAPID3. Infections, constitutional symptoms, and headaches were the most frequent AEs. Retention rate corresponded to 60% at 48 months. The most frequent reason for drug suspension was loss of efficacy. Median time of treatment for SC ABA was 31 months (IQR 30). The only association that reached statistical significance was anti-CCP concentration [Q1–Q4] (p = 0.005). According to the Cox proportional hazard regression model, there were significant differences between survival curves for Q1 (HR 0.15; 0.03–0.64 95% CI; p = 0.0096), and Q2 (HR 0.28; 0.08–0.92 95% CI; p = 0.0363) compared to the seronegative group.

Conclusions
The results showed an improvement in RA disease activity and physical function in patients under SC ABA treatment. Patients switching from IV to SC administration of ABA had lower activity and functional impairment at baseline. SC ABA demonstrated a good safety profile consistent with previously published data. Patients with baseline levels of anti-CCP antibody concentrations had better drug survival than seronegative patients.
Título traducido de la contribuciónAbatecept Subcutáneo en pacientes con artritis reumatoide: una experiencia en la vida real 2019
Idioma originalInglés
Páginas (desde-hasta)1024-1024
PublicaciónAnnals of the Rheumatic Diseases
Volumen75
N.º2
DOI
EstadoPublicada - jun 2016

Citar esto